I agree that if CTIX makes a good deal after the 2b trial, the SP will undoubtedly be double digits. Investors like free cash flow. It eliminates the fear of dilution. Furthermore, a successful 2b will open the flood gate for other indications. If Leo can find a partner for oral mucositis, eye infections, ear infections, in addition to ABSSSI, what would the SP be then?
Notice that I haven't even factored in the elephant in the room K and its little brother P. If all three are successful, a SP in the triple digits is all but certain. A buyout? Try to multiple the SP by 2 or 3.